Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Inscripta

Inscripta

A gene editing technology company founded in 2015 and based in Boulder, CO, USA.

Inscripta, founded in 2015 by Andrew Garst, Ryan T Gill and Tanya Lipscomb, provides gene editing tools for academic and commercial customers.In 2018 Inscripta acquired Solana Biosciences, a life sciences company founded by veterans of Illumina . Expansion plans include a new office in the life sciences hub of San Diego.

Inscripta has an enzyme engineering program rather than a particular application and they aim to provide tools for their customers to create their own applications faster.To tackle the lack of access and high cost of CRISPR gene-editing enzymes Inscripta is engineering CRISPR endonucleases called MADzymes.The DNA sequence for one MADzyme, MAD7 is provided free for any R&D use without reach-through royalty rights.MAD7 is derived from the genome of Eubacterium rectale and is a codon-optimized nuclease similar to Cpf1 (Cas12a). Inscripta is also engineering novel enzymes for exclusive use by industry partners.

Timeline

November 2020
Inscripta raises a $49,999,996 series D round from Korys.
December 10, 2019
Inscripta raises a $125,000,000 series D round from Foresite Capital, Merieux Equity Partners, NanoDimension, Oak HC/FT, Paladin Capital Group and Venrock.
April 4, 2019
Inscripta raises a $20,000,000 series C round from Foresite Capital, Merieux Equity Partners, NanoDimension, Paladin Capital Group and Venrock.
December 19, 2018
Inscripta raises a $30,000,000 series C round from Foresite Capital, Merieux Equity Partners, NanoDimension, Paladin Capital Group and Venrock.
February 28, 2018
Inscripta raises a $55,500,000 series C round from Foresite Capital, Merieux Equity Partners, NanoDimension, Paladin Capital Group and Spruce Capital Partners.
March 7, 2017
Inscripta was founded by Ryan T Gill.
February 28, 2017
Inscripta raises a $23,000,000 series B round from Foresite Capital, NanoDimension, Spruce Capital Partners and Venrock.
April 1, 2016
Inscripta raises a $6,000,000 series A round.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Andrea Park
April 5, 2021
FierceBiotech
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses. The genomic engineering company, a member of Fierce Medtech's 2019 Fierce 15, recently closed a series E funding round totaling $150 million.

References

Golden logo
By using this site, you agree to our Terms & Conditions.